Increase the success of in vitro fertilization by selecting the embryos with the best implantation potential

 

SATT Sud-Est transfers to DiaSys Technologies a biomarker that increases the chances of success of in vitro fertilization, thanks to the support of the Eurobiomed cluster

SATT Sud-Est announces an exclusive license on a co-ownership patent of Aix-Marseille Université, Inserm, Assistance Publique – Hôpitaux de Marseille, Centre Hospitalier Universitaire de Nîmes and Université de Montpellier, to DiaSys Technologies, an Occitan subsidiary of the DiaSys Diagnostics Systems Group (Germany), a leading developer and manufacturer of high quality diagnostic solutions. The license is for CD146 protein, an embryo selection biomarker with the best implantation potential for in vitro fertilization (IVF). The action of the health competitiveness cluster of the south of France Eurobiomed was decisive in bringing together its member, DiaSys Technologies, and SATT Sud-Est. It is the historic partnership between Eurobiomed and SATT Sud-Est that has made it possible to bring together the private and public research sectors.

Despite significant advances in reproductive biology, determining the number of embryos to be implanted in IVF remains a difficult step. To date, embryos are selected by microscopy according to imperfect morphological criteria, leading to multiple pregnancies or even pregnancy failures. Resulting from research at the Reproductive Biology Laboratory of the Conception Hospital in Marseille (AP-HM), the Cardiovascular and Nutrition Research Centre (C2VN UMR-S 1263), the laboratory “Dysfunction of Vascular Interfaces – Feminine Characteristics of Cardiovascular Interfaces” (EA nb 2992), and the Hematology Laboratory of the University Hospital of Nîmes, the technology offers a new non-invasive tool to accurately determine the embryos with the best chances of success in IVF based on the expression level of CD146 protein in the embryo culture medium.

Logotype de DiaSys Technologies

SATT Sud-Est has filed and manages a patent that protects the technology. Co-maturation and sub-licensing agreements have been signed between SATT Sud-Est and DiaSys Technologies. Objectives: to validate the results on an extended cohort and adapt the biomarker assay to DiaSys Technologies’ proprietary technology. DiaSys Technologies will develop and propose a new kit for the analysis of the chances of success of embryo implantation for medically assisted reproduction services. Read more, download press release.

For further information

 

Twitter

@SATTse_ @univamu @Insermpacacorse @aphm_actu @CHUNimes @umontpellier @PoleEurobiomed